What is BioCryst Pharmaceuticals Inventory-to-Revenue?
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BioCryst Pharmaceuticals's Average Total Inventories for the quarter that ended in Dec. 2023 was $29.2 Mil. BioCryst Pharmaceuticals's Revenue for the
three
months ended in Dec. 2023 was $93.4 Mil.
BioCryst Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.31.
BioCryst Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023
declined
from Sep. 2023 (0.33) to Sep. 2023 (0.31)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
BioCryst Pharmaceuticals's Days Inventory for the
three
months ended in Dec. 2023 was 1,625.25.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioCryst Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.06.
BioCryst Pharmaceuticals Inventory-to-Revenue Historical Data
The historical data trend for BioCryst Pharmaceuticals's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioCryst Pharmaceuticals's Inventory-to-Revenue
For the Biotechnology subindustry, BioCryst Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCryst Pharmaceuticals's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioCryst Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
BioCryst Pharmaceuticals's Days Inventory for the
three
months ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Business Description
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BCRX has been successfully added to your 